Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Amgen’s Humira Biosimilar Gets FDA Green Light

XTALKS VITALS NEWS

Biosimilar

As well as becoming Amgen’s first biosimilar to receive regulatory approval, Amjevita has been approved for all seven indications of the reference product, including moderate-to-severe rheumatoid arthritis, psoriatic arthritis and moderate-to-severe ulcerative colitis.

Tweetables from this article:

Tweet: Amjevita is Amgen’s first #biosimilar to receive regulatory approval http://ctt.ec/379gW+Amjevita is Amgen’s first biosimilar to receive regulatory approval.

Share this!

September 27, 2016 | by Sarah Hand, M.Sc.

In a major win for Amgen, the US Food and Drug Administration (FDA) has approved Amjevita (adalimumab-atto), a biosimilar of AbbVie’s Humira (adalimumab). As well as becoming Amgen’s first biosimilar to receive regulatory approval, Amjevita has been approved for all seven indications of the reference product, including moderate-to-severe rheumatoid arthritis, psoriatic arthritis and moderate-to-severe ulcerative colitis.

“Approval of Amjevita is an exciting accomplishment as it marks a new chapter in Amgen's story of being a leader in biotechnology. In addition, Amjevita holds the potential to offer patients with chronic inflammatory diseases an additional treatment option,” said Dr. Sean E. Harper, executive vice president of Research and Development at Amgen. “This milestone exemplifies our ongoing dedication to the development of high quality biologic medicines.”



Both Amjevita and Humira are anti-TNF-α monoclonal antibodies. Not only does Amjevita have the same amino acid sequence as the active ingredient in Humira, but it has also been deemed highly similar to the biologic.

Amgen submitted analytical, nonclinical, pharmacokinetic and clinical data to the FDA, in order to support Amjevita’s claim of biosimilarity to adalimumab. In addition, two phase III clinical trials in moderate-to-severe plaque psoriasis and moderate-to-severe rheumatoid arthritis showed the drug met its primary endpoint of equivalency to Humira.

“This is the fourth FDA-approved biosimilar,” said Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research. “The biosimilar pathway is still a new frontier and one that we expect will enhance access to treatment for patients with serious medical conditions.”

As a biosimilar, Amjevita is also subject to the same FDA-mandated boxed warning as Humira. The warning alerts doctors and patients to the risks associated with the drugs’ use, including increased risk of infections, hospitalization and death. In addition, a comprehensive patient medication guide must be provided along with the drug that explains the indications and risks for both the branded biologic and the biosimilar.

Amgen is still waiting for the European Medicines Agency’s (EMA) decision on Amjevita, after applying for approval in late 2015. In all, Amgen has nine ongoing projects in its biosimilar pipeline, including the newly-approved adalimumab.


Keywords: Biosimilar, FDA, Rheumatoid Arthritis


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Exclusion Criteria for Clinical Trials Poses Major Barrier to Patient Enrollment

August 17, 2017 - UT Southwestern researchers say that clinical investigators continue to increase the number of exclusion criteria, preventing more patients from participating in clinical trials.

Featured In: Clinical Trials News


Targeting Cellular Nitrogen Metabolism Could Offer a New Treatment for Pancreatic Cancer

August 17, 2017 - An enzyme involved in regulating the amount of nitrogen in the cell could be a new drug target for pancreatic cancer, according to researchers from Boston Children's Hospital and the Broad Institute of MIT and Harvard.

Featured In: Life Science News


Regeneron’s Drug for Respiratory Syncytial Virus Fails in Phase III Clinical Trial

August 16, 2017 - Biotechnology company Regeneron has announced it will not continue development of its antibody drug, suptavumab, after a failure in a Phase III clinical trial.

Featured In: Clinical Trials News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

One Patient’s Perspective on Clinical Trials

REGISTER FOR THESE WEBINARS

Planning and Conducting Trials of the Latest Immunotherapies


ISO 13485:2016 for Medical Device Manufacturers: Ensuring a Smooth Transition through Effective Preparation


Medical Devices: Reviewing Regulatory Changes in the US and EU


Moving Beyond Regulatory and Performance Metrics in Starting Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.